Alopecias: Diagnostic Clues and Nuances in Clinical Presentation
Hair loss is a broad category that can be difficult for dermatology clinicians to manage. Having a scripted or algorithmic approach to alopecia consults can decrease clinician anxiety, says Dr. Adam Friedman, co-chair of the ODAC Dermatology, Aesthetic & Surgical Conference. Next Steps in Derm, in partnership with ODAC, interviewed Dr. Friedman, who shared his approach for evaluating alopecia …
Hair loss is a broad category that can be difficult for dermatology clinicians to manage. Having a scripted or algorithmic approach to alopecia consults can decrease clinician anxiety, says Dr. Adam Friedman, co-chair of the ODAC Dermatology, Aesthetic & Surgical Conference. Next Steps in Derm, in partnership with ODAC, interviewed Dr. Friedman, who shared his approach for evaluating alopecia … Continue reading "Alopecias: Diagnostic Clues and Nuances in Clinical Presentation"
Sunscreen use varies among different racial groups despite its scientifically proven benefits. A cross-sectional, questionnaire-based study in the June issue of the Journal of Drugs in Dermatology aims to understand the needs and challenges people with skin of color face when choosing and using sunscreen.
I interviewed author Jared Jagdeo, MD, MS, associate professor of dermatology and director … 
Recent studies on the risks of vascular occlusions and the safety of cannulas versus needles have impacted the way Dr. Robyn Siperstein educates and consents her patients. Next Steps in Derm, in partnership with ODAC Dermatology, Aesthetic & Surgical Conference, interviewed Dr. Siperstein, a dermatologist in Boca Raton and Boynton Beach, Fla. Hear why Dr. Siperstein says a paper by Dr. Murad … 
Skin boosters are a new category of injectables approved by the FDA. These products are low concentration hyaluronic acid gels that improve skin quality, including smoothness, luminosity and hydration. Next Steps in Derm, in partnership with ODAC Dermatology, Aesthetic & Surgical Conference, interviewed Dr. Terrence Keaney, associate clinical professor of dermatology at GW School of Medicine & … 
Cemiplimab is a monoclonal antibody therapy that has emerged as a promising treatment option for certain types of advanced skin cancer. Specifically designed to target the programmed cell death protein 1 (PD-1) pathway, cemiplimab works by blocking the interaction between PD-1 and its ligands, PD-L1 and PD-L2, thereby unleashing the body's immune system to recognize and attack cancer cells. We con …